-
8881“…Although a vaccine has been developed to prevent hepatitis C and E viruses, its use is not licensed worldwide. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8882por Zaki, Marco Y. W., Fathi, Ahmed M., Samir, Samara, Eldafashi, Nardeen, William, Kerolis Y., Nazmy, Maiiada Hassan, Fathy, Moustafa, Gill, Upkar S., Shetty, Shishir“…SIMPLE SUMMARY: Infections with Hepatitis B and Hepatitis C viruses are usually asymptomatic and although some patients undergo resolution of infection, the majority do not. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8883por Queiroz, Maria Alice Freitas, Santiago, Angélica Menezes, Moura, Tuane Carolina Ferreira, Amoras, Ednelza da Silva Graça, Conde, Simone Regina Souza da Silva, Cayres-Vallinoto, Izaura Maria Vieira, Ishak, Ricardo, Vallinoto, Antonio Carlos Rosário“…Patients with HCV were associated with increased inflammatory activity (A2–A3; p < 0.0001). In hepatitis C, carriers of the GG genotype had higher levels of IL-6 (p = 0.0286), which were associated with A2–A3 inflammatory activity (p = 0.0097). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8884“…A linear growth of IE has occurred over the past several years in Saskatchewan, with overlapping epidemics of human immunodeficiency virus (HIV)/hepatitis C virus driven by injection drug use (IDU). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8885por Yarkan Tugsal, Handan, Yuksel, Selcen, Kabacam, Gokhan, Evirgen, Sami, Akan, Kubra, Akyuz, Filiz, Gulluoglu, Mine, Erden, Esra, Bozdayi, A. Mithat, Cinar, Kubilay, Idilman, Ramazan, Yurdaydin, Cihan, Kaymakoglu, Sabahattin, Bozkaya, Hakan“…The FIB-4 Index was applied to the CHC study cohort and the ATA Index Hepatitis C was found to be superior in terms of AUC (0.89–0.82), sensitivity (0.91–0.76) and NPV (0.96–0.86). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8886por Nevola, Riccardo, Rosato, Valerio, Conturso, Vincenza, Perillo, Pasquale, Le Pera, Teresa, Del Vecchio, Ferdinando, Mastrocinque, Davide, Pappalardo, Annalisa, Imbriani, Simona, Delle Femine, Augusto, Piacevole, Alessia, Claar, Ernesto“…SIMPLE SUMMARY: The global fight against the hepatitis C virus (HCV) involves the processes of micro-elimination of populations at risk. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8887“…A recent study has shown that the hepatitis C virus changes the TME by inducing pyroptosis against hepatocellular carcinoma (HCC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8888por Silva, Tânia Maria Pazin Marques, Ferreto, Lirane Elize Defante, Follador, Franciele Ani Caovilla, Vieira, Ana Paula, Yamada, Roberto Shigueyasu, Lucio, Léia Carolina, Titon, Joana Perotta, Torres, Renata Himovski, Amaral, Greicy Cézar do, Coelho, Harnoldo Colares“…The objective of this study was to identify features associated with hepatitis C infection among male prisoners in correctional institutions of Paraná state, Brazil. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8889por Garand, Mathieu, Huang, Susie S. Y., Goessling, Lisa S., Santillan, Donna A., Santillan, Mark K., Brar, Anoop, Wylie, Todd N., Wylie, Kristine M., Eghtesady, Pirooz“…Human pegivirus (HPgV) is best known for persistent, presumably non-pathogenic, infection and a propensity to co-infect with human immunodeficiency virus or hepatitis C virus. However, unique attributes, such as the increased risk of malignancy or immune modulation, have been recently recognized for HPgV. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8890por Pham, Long V., Velázquez-Moctezuma, Rodrigo, Fahnøe, Ulrik, Collignon, Laura, Bajpai, Priyanka, Sølund, Christina, Weis, Nina, Holmbeck, Kenn, Prentoe, Jannick, Bukh, Jens“…Hepatitis C virus (HCV) genotype 4 is highly prevalent in the Middle East and parts of Africa. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8891por Badr, Eman A. E., Elmongy, Elshaymaa I., Mostafa, Rasha Galal, El-Sayed, Ibrahim El-Tantawy, Abd El-Ati Gad Allah, Abd El-Naser, Khairy Ahmed, Asmaa, Elghobashy, Yasser A. S.“…Background: Hepatocellular carcinoma (HCC) is the most common histologic type of primary liver cancers worldwide. Hepatitis C virus (HCV) infection remains a major risk factor for chronic liver disease, cirrhosis, and HCC. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8892“…Our patient's history of intravenous drug use and active Hepatitis-C infection were typical risk factors associated with invasive infections. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8893por Eris, Tansu, Hassan, Moomen, Hikal, Yousra, Sawah, Enas, Daneshgar, Fatemeh, Teker, Ayse Gulsen, Ozel, Furkan, Luleci, Nimet Emel, Kaya, Eda, Yilmaz, Yusuf“…Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597–3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168–3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524–2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360–3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8894“…Thioacetamide (TAA) exposure and hepatitis C virus infection are usually associated with renal dysfunction. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8895por Legese, Haftom, Berhe, Brhane, Adhanom, Gebre, Kahsay, Tsega, Gebrewahd, Aderajew, Gebremariam, Guesh, Mardu, Fitsum, Tesfay, Kebede, Gebremedhin, Haftay, Negash, Hadush“…Additionally, 2.49%( 12/481) of males and 1.94% (18/924) of females were positive for hepatitis C virus infection. The overall prevalence of co-infection for both hepatitis B and hepatitis C virus was 7.4% (4/54). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8896por Friedman, Eleanor E., Shankaran, Shivanjali, Devlin, Samantha A., Kishen, Ekta B., Mason, Joseph A., Sha, Beverly E., Ridgway, Jessica P.“…Our final model had an AUC of 0.74 and included healthcare site, age group, race, ethnicity, pregnancy, hepatitis C, substance use, and STI diagnosis. CONCLUSIONS: Our predictive model showed acceptable discrimination between those who were and were not newly diagnosed with HIV. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8897“…There were 6.7 HIV cases, 136.0 early syphilis and gonorrhea cases, and 109.1 acute and chronic hepatitis C cases per 100K population. Per HIV diagnosis, there were 2.6 PrEP starts and 1.5 prevalent users. …”
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8898“…Several viruses have been associated with the development of inflammatory arthritis, including the hepatitis viruses (hepatitis B virus and hepatitis C virus), HIV, the parvovirus B19, the human T-cell lymphotropic virus-I, and the alphaviruses. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
8899“…Cryoglobulinemia is an uncommon cause of renal disease and often occurs in patients with hepatitis C virus (HCV) infection. We report a case of membranoproliferative glomerulonephritis in a patient with cryoglobulinemia, which was not associated with HCV infection or any identifiable etiology.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
8900por Garimella, Tushar, Tao, Xiaolu, Sims, Karen, Chang, Yi-Ting, Rana, Jignasa, Myers, Elsa, Wind-Rotolo, Megan, Bhatnagar, Rahul, Eley, Timothy, LaCreta, Frank, AbuTarif, Malaz“…BACKGROUND: A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus genotype 1. …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto